HYA
LIVE

Serial Number

79249944

Owner

Noster Inc.

Filing Date

Sep 20, 2018

Add to watchlist:

No watchlists yet
View on USPTO

HYA Trademark

Serial Number: 79249944 • Registration: 5929291

HYA is a trademark filed by Noster Inc. on September 20, 2018. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 16 (Paper Goods), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Noster Inc. (26 trademarks)

35-3, Minamibiraki,

Entity Type: 99

NITTO PHARMACEUTICAL INDUSTRIES, LTD. (14 trademarks)

35-3, Minamibiraki,

Entity Type: 03

Trademark Details

Filing Date

September 20, 2018

Registration Date

December 10, 2019

Published for Opposition

September 24, 2019

Goods & Services

Pharmaceutical preparations other than for agricultural purposes for the treatment and prevention of metabolic and endocrine diseases, namely, diabetes, diabetic complication, hyperlipidemia, hyperuricemia, gout, lifestyle related disease, nutritional disorders, impaired glucose tolerance, metabolic syndrome, obesity and lipid disorder, cardiovascular, urological and reproductive diseases, namely, hypertension, hyperglycemia, ischemic heart disease, hyperinsulinemia, arteriosclerosis, myocardial infarction, angina pectoris, aneurysm, chronic kidney disease, renal calculi, kidney disease, pyelonephritis, nephritis, urethritis, cystitis, hypercholesterolemia and high triglyceridemia, respiratory diseases, namely, bronchitis, pulmonary emphysema and lung inflammation, digestive and oral diseases, namely, abnormality of the intestinal flora, abdominal distension, peptic ulcer, intestinal disease, inflammatory disorder, irritable bowel syndrome, gastric ulcer, inflammatory bowel disease, Crohn's disease, diverticulitis, liver cirrhosis, fatty liver, diarrhea, constipation, loose stool disease, hepatic inflammation, non-alcoholic steatohepatitis, viral hepatitis, alcoholic hepatitis, dental disease, periodontal diseases, stomatitis, xerostomia and cyst, immune, inflammatory and allergic diseases, namely, immune related diseases and abnormalities, type I, II, III, IV and V allergy, pollinosis, atopic dermatitis, psoriasis, autoimmune disease and connective tissue disease, bone and articular diseases, namely, rheumatism, osteoporosis and articular inflammation, pathogenic microbial and malignant neoplastic diseases, namely, infection, cancer and malignant tumor, mental and nervous system diseases, namely, mental disorder, dementia, Alzheimer's disease, bipolar disorder, depression, anorexia, insomnia, cerebral apoplexy, cerebral infarction, autism, neuroinflammation, overwork related disease and nerve inflammation related diseases and cancers resulting from chronic inflammation, and sensory system and skin diseases, namely, ophthalmic disease, ocular inflammation, otorhinolaryngology disease and skin inflammation; pharmaceutical preparations in the nature of medicines for dental purposes; reagent paper for medical purposes; oiled paper for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceutical for medicine doses; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; liquid bandages; antiseptic liquid bandages; breast-nursing pads; dental composite, impression and porcelain materials; dental materials, namely, dental porcelain materials, materials for making dental impressions and composite materials for dental and dental technical purposes; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic food adapted for medical purposes; beverages for babies, namely, human breast milk, powdered milk, isotonic beverages for babies; food for babies; dietary supplements for animals

Paper and cardboard; printed matter, namely, paper signs, books, manuals, curricula, newsletters, information cards and brochures in the field of health

Advertising and publicity services

Chemicals, namely, chemical additives for use in the manufacture of food, pharmaceuticals, cosmetics and animal feed; perfluorinated chemical compounds prepared synthetically for use in the manufacture of cosmetics and pharmaceuticals; food preserving chemicals; chemical preparations for preserving foodstuffs; chemical products for the fresh-keeping and preserving of food; chemical products for stabilizing foodstuffs; chemicals for industrial purposes; chemicals for use in the manufacture of a wide variety of goods; glue and adhesives for industrial purposes; plant growth regulating preparations; fertilizers; higher fatty acids for industrial purposes; chemical compositions for developing, printing and enlarging photographs; unprocessed plastics

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Dec 10, 2024 REM3
CHANGE OF OWNER RECEIVED FROM IB
Feb 12, 2021 CHLD
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 10, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 24, 2020 FICS
FINAL DISPOSITION PROCESSED
Mar 24, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 10, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Dec 10, 2019 R.PR
NOTIFICATION PROCESSED BY IB
Oct 5, 2019 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 24, 2019 NPUB
PUBLISHED FOR OPPOSITION
Sep 24, 2019 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 18, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sep 18, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 4, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 19, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 25, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 25, 2019 CRFA
ASSIGNED TO LIE
Jul 22, 2019 ALIE
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 17, 2019 TCCA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 17, 2019 TROA
REFUSAL PROCESSED BY IB
Mar 2, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 8, 2019 RFCS
REFUSAL PROCESSED BY MPU
Feb 8, 2019 RFRR
APPLICATION FILING RECEIPT MAILED
Jan 29, 2019 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 26, 2019 RFCR
NON-FINAL ACTION WRITTEN
Jan 25, 2019 CNRT
ASSIGNED TO EXAMINER
Jan 25, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 25, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 24, 2019 REPR